top of page

Actxa and Joint Chinese Limited Launch Actxa’s Non-Invasive Blood Glucose Monitoring Tech

A virtual collaboration between Actxa and Joint Chinese Limited on the launch of Actx'a Non-Invasive blood glucose monitoring technology.

The MOU was signed by Mr Joel Chin, CEO of Actxa (left), and Mr James Yan, CEO of Joint Chinese Limited (right). Photo by: Actxa Pte Ltd

Singapore, 3 August 2022 – Actxa Pte. Ltd (“Actxa”) and Joint Chinese Limited (“JC”) alongside its associated group of companies, signed a Memorandum of Understanding (“MOU”) on 2 August 2022, to join hands in market penetration and expansion for Pre-M Diabetes, also known as the Non-Invasive Blood Glucose Monitoring technology. We will be targeting the consumer wearables, senior care and home care segment in China. Both will also work closely on the worldwide distribution of JC’s wearables powered by Pre-M Diabetes.

Actxa and JC will collaborate to incorporate Pre-M Diabetes and other physiological health insights (“Actxa Insights”) in JC’s products and services, develop business and establish marketing and brand presence in China. Both sides will also be involved in research collaborations in China to further develop Actxa Insights.

JC is a leading manufacturer and solution provider for digital health wearables in China. JC has identified at least 11 models of their wearables that have the potential to include Pre-M Diabetes to ship within China and worldwide.

Actxa is the first Singapore company to develop a comprehensive AI solution that leverages consumer-grade wearables to detect blood glucose dysregulation. The Pre-M Diabetes is also the only non-invasive blood glucose detection solution to be going through a clinical validation study in Southeast Asia.

In Singapore, at least 1 million people are projected to have diabetes by 2050 and 1 out of 4 will be undiagnosed¹. Worldwide, about 643 million people will be diabetic by 2030, and 1 in 2 adults will be undiagnosed². Through regular blood glucose monitoring, the increased risk for developing diabetes can be detected early.

The launch of the Pre-M Diabetes allows individuals to monitor their blood glucose levels in a pain-free, easy and frequent way. The regular measurement of blood glucose will help individuals prevent, delay the onset or in some situations, even reverse the condition.

Joel Chin, Actxa’s Chief Executive Officer, said, “This MOU builds on our existing strong partnership with JC, and we are honoured to collaborate with JC in launching and distributing the Pre-M Diabetes in China and the rest of the world.

This strategic alliance leverages the strengths of both companies to create a significant impact in the global fight against diabetes. We are confident that Pre-M Diabetes will help individuals make informed health decisions and positive lifestyle changes to reduce the risk of developing Type 2 diabetes.”

Mr. James Yan, Chief Executive Officer of Joint Chinese Limited, said, “Actxa and Joint Chinese Limited are forerunners in wearable technology, and the cooperation between the two parties has entered the eighth year. Focusing on cutting-edge technologies related to human health, both teams have constantly worked together to improve the synergy and uncover tacit knowledge to drive more innovation. The accuracy of data collection has also improved.

The series of Pre-M Diabetes products is the result of our joint efforts, boosting new opportunities in the global preventive health market. Joint Chinese Limited will continue to sustain and pursue quality work, while achieving success with Actxa.”

The Pre-M Diabetes has also won Actxa an award under the AI – Healthcare Technology category in the annual SBR Technology Excellence Awards, hosted by Singapore Business Review. The SBR Technology Excellence Awards is part of the regional Asian Technology Excellence Awards now running in 50 countries³.



For further information, please contact:

Tan Lay Eng Communications Manager +65 9877 0406

Hasyimah Begum AJ Communications Executive +65 8780 3620

About Actxa

Actxa was founded in 2015 with the mission to bring together people, partners, science, technology, and data to create positive changes to the health, quality of life and well-being of individuals and communities.

Leveraging our expertise in developing evidence-based and personalised insights through Artificial Intelligence, we empower individuals to make informed decision on their health and well-being and to make timely changes to their lifestyle. Actxa sets its focus on research and development on innovative preventive health solutions, and we work closely with industry and academic partners to explore new opportunities.

For more information, visit

About Joint Chinese Group

Founded in 2004, Joint Chinese Ltd. is a High-tech manufacturer with Medical Qualification, specialized in Smart Health & Medical Care Product in China. We have 3 production bases with total of 20,000sqm and strong R&D team of more than 120 engineers. We operate in 100+ countries and regions, collaborating with most recognized brands, including Xiaomi, Walmart, LG. Specialized in OEM/ODM one-stop service, we have plant area of 12,000 sq meter with monthly production capacity of 1000,000 pcs.

For more information, visit


bottom of page